Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.26 - $5.31
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.18M
Market Cap
$555.88M
Enterprise Value$491.92M
Total Cash (Recent Filing)$19.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 08, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding172,633,130
10 Day Avg. Volume680,100
30 Day Avg. Volume1,178,410
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.81
Forecast
1Y Price Target
$7.10Price Target Upside117.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Savara News
PremiumCompany Announcements
Savara Secures $200 Million Loan Agreement with Hercules
PremiumCompany Announcements
Savara Sets 2025 Executive Bonus Targets---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySVRA had $219M in cash, providing a financial runway through 2Q27, and the debt deal with Hercules gives the company breathing room for the early launch.
Market PotentialMolbreevi is expected to be a blockbuster product with potential peak sales of about $1.2B.
Regulatory ApprovalAnalysts are highly confident in Molbreevi's regulatory approval due to positive Phase III data showing benefits on lung function.
Bears Say
Diagnosis ChallengesAPAP can be misdiagnosed with similar symptoms to pneumonia, bronchitis, or asthma, resulting in delayed accurate diagnosis.
Regulatory TimingThe completion of Molbreevi's rolling BLA submission sets up a potential PDUFA in late November or early December, creating uncertainty in approval timing.
---
Ownership Overview
12.64% Insiders
8.61% Mutual Funds
0.02% Other Institutional Investors
69.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.25 and its highest was $5.31 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $555.88M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were Savara’s earnings last quarter?
Savara released its earnings results on Mar 27, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.114 by -$0.016.
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.13.
How many shares outstanding does Savara have?
Savara has 172,633,130 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Savara reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.114. Following the earnings report the stock price went up 2.963%.
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
---
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.10 (117.13% Upside)
$7.10 (117.13% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $415.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.70%
12-Months-Change
Fundamentals
Return on Equity
-61.50%
Trailing 12-Months
Asset Growth
19.89%
Trailing 12-Months
Company Description
Savara
Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare respiratory diseases. The company's primary therapeutic area includes conditions such as pulmonary alveolar proteinosis (PAP) and idiopathic pulmonary fibrosis (IPF). Savara's lead product candidate is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), which is currently in clinical development for the treatment of PAP.
---
SVRA Stock 12 Month Forecast
Average Price Target
$7.10
▲(117.13% Upside)
Technical Analysis
Kura Oncology
―
Niagen Bioscience
―
Urogen Pharma
―
Arvinas Holding Company
―
Bicycle Therapeutics
―
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+13.60%
assigned a buy rating 7 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.60% per trade.
---